KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 90 filers reported holding KALVISTA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $79,755 | +5.2% | 10,147 | -9.5% | 0.00% | – |
| Q4 2022 | $75,834 | -57.4% | 11,218 | +9.7% | 0.00% | – |
| Q3 2021 | $178,000 | -95.2% | 10,222 | -93.4% | 0.00% | -100.0% |
| Q2 2021 | $3,734,000 | +4398.8% | 155,840 | +1331.8% | 0.00% | – |
| Q1 2020 | $83,000 | -36.2% | 10,884 | -3.3% | 0.00% | – |
| Q3 2019 | $130,000 | -97.7% | 11,257 | -95.6% | 0.00% | -100.0% |
| Q2 2019 | $5,729,000 | -36.2% | 258,673 | -17.6% | 0.00% | -66.7% |
| Q1 2019 | $8,980,000 | +64.4% | 313,791 | +13.5% | 0.00% | +50.0% |
| Q4 2018 | $5,461,000 | – | 276,523 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 719,937 | $6,697,459 | 5.56% |
| TCG Crossover Management, LLC | 3,395,495 | $22,953,546 | 4.05% |
| VR Adviser, LLC | 2,916,667 | $19,716,669 | 3.32% |
| TANG CAPITAL MANAGEMENT LLC | 3,196,446 | $21,607,975 | 3.14% |
| Prosight Management, LP | 621,667 | $4,202,469 | 2.29% |
| Opaleye Management Inc. | 923,200 | $6,240,832 | 2.17% |
| GREAT POINT PARTNERS LLC | 1,055,801 | $7,137,215 | 1.40% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $21,894,687 | 1.36% |
| DAFNA Capital Management LLC | 616,032 | $4,164,376 | 1.17% |
| Vivo Capital, LLC | 856,008 | $5,787 | 0.67% |